Toronto-based Bloom Burton, a healthcare services company, has named Oliver Technow, former CEO of Charlottetown-based BIOVECTRA, the winner of the 2025 Bloom Burton Award, which recognizes a remarkable contribution to the healthcare sector.

“We are privileged to celebrate Oliver Technow and the success of BIOVECTRA, a crown jewel for Prince Edward Island and all of Canada,” said Brian Bloom, Chairman and CEO of Bloom Burton in a statement.

“During Oliver’s tenure from 2015 to 2024, he secured investment from H.I.G. Capital, attracted top international talent, and expanded the company to nearly 700 employees, across eight facilities, in two maritime provinces. In 2024, BIOVECTRA was acquired by Agilent for US$925 million, a partnership that continues to champion the company’s Canadian roots and capabilities.”

Every year, the Bloom Burton Award honours a scientist, inventor, executive, entrepreneur, industry leader, or policy maker who contributed to Canada’s innovative healthcare industry. Nominees were accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or digital health sectors. Equal consideration was given to contributions across any stage of development, from discovery to commercial-end markets, the group said.

All finalists --Technow, Mark Nawacki of Searchlight Pharma, and Ali Tehrani, formerly of Zymeworks -- were celebrated at the 2025 Bloom Burton Award Gala in Toronto this week. Each finalist also received a $25,000 cash prize.